PainReform Completes DeepSolar Acquisition for Growth in AI Solar Analytics
Deal News | Mar 05, 2025 | Globenewswire
PainReform Ltd., a specialty pharmaceutical company, successfully completed the acquisition of DeepSolar, an AI-driven solar analytics company, from BladeRanger Ltd. in Tel Aviv, Israel. This strategic acquisition marks PainReform's foray into the clean energy sector by integrating DeepSolar's AI-driven solutions to optimize solar energy asset management. DeepSolar's software enhances solar farm efficiency by integrating predictive maintenance and actionable insights that optimize energy production and reduce operational costs, thereby boosting solar asset profitability. The acquisition aims to generate recurring revenues via a SaaS model, reduce customer operational expenses by 30%, and penetrate broader markets that include utility-scale operators, independent producers, and residential users. With the solar market growing rapidly, DeepSolar solutions target inefficiencies in asset management, providing significant market opportunities for PainReform. Ehud Geller, Chairman and interim CEO of PainReform, confirms this acquisition aligns with PainReform's strategy to invest in high-margin technology sectors, while continuing to advance their pharmaceutical innovations. As part of the acquisition, PainReform will issue shares and warrants to BladeRanger Ltd., subjecting BladeRanger to shareholding limitations. Additionally, key DeepSolar management will join PainReform, which views this investment as a means to capitalize on the global transition to clean energy and expand revenue channels.
Sectors
- Renewable Energy
- Pharmaceuticals
- Technology
Geography
- Israel – PainReform and DeepSolar are both based in Israel, where the acquisition transaction occurred.
Industry
- Renewable Energy – The acquisition involves the solar sector which forms a part of the renewable energy industry, focusing on optimizing solar energy management through AI-driven analytics.
- Pharmaceuticals – PainReform is primarily a specialty pharmaceutical company focusing on drug reformulation and innovation.
- Technology – The integration of AI-driven solutions for solar asset management positions this within the technology sector as it enhances the technological capabilities for energy production.
Financials
- 178,769 ordinary shares – Issued to BladeRanger Ltd. representing 9.9% of PainReform's issued and outstanding share capital post issuance.
- 223,792 pre-funded warrants – Granted to BladeRanger Ltd. to purchase the same number of ordinary shares.
- 685,004 pre-funded milestone warrants – To be issued for the purchase of ordinary shares following the increase of PainReform's share capital.
- 1,087,565 warrants-A and B – To be issued for purchasing ordinary shares as part of the transaction with BladeRanger Ltd.
Participants
Name | Role | Type | Description |
---|---|---|---|
PainReform Ltd. | Buyer | Company | A clinical-stage specialty pharmaceutical company focused on drug reformulation and new therapeutic development. |
DeepSolar | Target | Company | An AI-driven solar analytics platform focused on optimizing solar energy asset management. |
BladeRanger Ltd. | Vendor | Company | The public company that sold the business activities of DeepSolar to PainReform. |
Ehud Geller | Chairman and interim CEO of PainReform | Person | Leader at PainReform providing insights about the strategic acquisition and its expected benefits. |